JHEP Reports

Article	Citations
Increased carbohydrate deficient transferrin: Whisky or candy?	154
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	148
Copyright and information	118
The Weight of Choices: Prioritizing Lifestyle Over GLP-1 Receptor Agonist Therapy in Managing MASLD	116
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	106
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”	104
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	104
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	102
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	94
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	73
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	69
Predicting liver ablation volumes with real-time MRI thermometry	68
Copyright and information	63
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	57
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	55
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	55
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	53
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	48
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	48
Emerging roles of circular RNAs in liver cancer	47
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	47
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	47
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	46
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	46
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	46

Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	44
Epigenetics of alcohol-related liver diseases	44
A small animal model of chronic hepatitis E infection using immunocompromised rats	42
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: a challenge for surveillance?	41
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis	40
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	40
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	40
Copyright and information	39
Editorial Board page	39
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	38
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency	38
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH	38
Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine	38
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV	37
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis	37
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	37
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle	36
Deep learning can predict cardiovascular events from liver imaging	35
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model	35
Contents	34
Understanding virologic heterogeneity in chronic hepatitis B treatment	34
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	34
Arachidonic acid activates NLRP3 inflammasome in MDSCs via FATP2 to promote post-transplant tumour recurrence in steatotic liver grafts	33
Editorial Board page	33
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	32
Editorial Board page	32
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	31
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	31
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	30
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	30
Dual-tracer PET/CT in the management of hepatocellular carcinoma	29
Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein	29
Contents	29
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries	28
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine	28
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy	28
Corrigendum to: ‘Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia’ (JHEP Reports, Volume 6, Issue 7, July 2024, 101090)	27
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	27
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis	27
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	26
Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”	26
Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”	26
Non-invasive biomarkers of Fontan-associated liver disease	26
Application of a deep learning algorithm for the diagnosis of HCC	25
Regulatory T cell therapy in autoimmune liver disease and transplantation	25
Minimal residual ascites three months after TIPS implantation indicates worse clinical outcome in patients with liver cirrhosis	25
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet	25
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy	25
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆	25
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis	25

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis	24
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	24
Hepatocyte proteomes reveal the role of protein disulfide isomerase 4 in alpha 1-antitrypsin deficiency	24
Editorial Board page	23
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity	23
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors	22
A nationwide population-based prospective study of cirrhosis in Iceland	22
Good long-term outcomes of primary sclerosing cholangitis in childhood	22
Corrigendum to ‘A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation’ [JHEP Reports 6	22
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab	22
Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum	21
Does ammonia really disrupt brain oxygen homeostasis?	21
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma	21
Second-line pembrolizumab for advanced HCC: meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies	21
Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma	21
Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation	21
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	20
The role of cGAS-STING signalling in liver diseases	20
Reply to: “Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?”	20
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis	20
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis	20
Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers	20
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis	19
Copyright and information	19
Prevalence of Rocahepevirus ratti (rat hepatitis E virus) in humans and rats in China	19
Estimating the clinical prevalence of Wilson’s disease in the UK	19
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	19
Acknowledging our reviewers	19
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis	19
Should all pediatric patients with type 1 autoimmune hepatitis be screened for inflammatory bowel disease?	18
Circadian control of ConA-induced acute liver injury and inflammatory response via Bmal1 regulation of Junb	18
Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial	18
DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids	18
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy	18
Hepatic microbiome in healthy lean and obese humans	18
LAPTM4B enhances the stemness of CD133+ liver cancer stem-like cells via WNT/β-catenin signaling	18
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	18
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosis	18
High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment	18
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	18
Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure	18
Embedding assessment of liver fibrosis into routine diabetic review in primary care	18
Thyroid dysfunction in MASLD: Results of a nationwide study	17
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	17
Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes	17
Minimally-invasive hepatectomy versus thermoablation for single small (<=3cm) hepatocellular carcinoma: a weighted real-life national comparison.	17
Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis	17
Liver specification of human iPSC-derived endothelial cells transplanted into mouse liver	17
Contents	17
Innovative approaches to the management of ascites in cirrhosis	17
Evolving epidemiology of HCC in Spain	17
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis	17
Editorial Board page	16
Traditional lifestyle factors partly mediate the association of socioeconomic position with intrahepatic lipid content: The Maastricht study	16
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study	16
Distribution of non-ceruloplasmin-bound copper after i.v. 64Cu injection studied with PET/CT in patients with Wilson disease	16
Editorial Board page	16
Contents	16
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis	16
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort	15
Single cell analysis of mature hepatocytes reveals an IRF1 driven restriction of HDV infection.	15
Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras	15
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy	15
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	15
Corrigendum to ‘Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation’ [JHEP Reports 6 (2024) 100983]	15
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation	15
Contents	15
Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer	15
B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation	15
Erratum to ‘Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease’ (JHEP Reports 5 [2023] 100836)	15
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1	15
ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome	15
Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma	14
Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease	14
Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation	14
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV	14
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease	14
Surveillance for hepatocellular carcinoma in patients with Primary Biliary Cholangitis: for all or just for some?	14
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes	14
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice	14

Transcriptomic landscapes of effective and failed liver regeneration in humans	14
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse	14
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	14
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications	13
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	13
Immunomodulatory receptor VSIG4 is released during spontaneous bacterial peritonitis and predicts short-term mortality	13
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component	13
Waiting time dictates impact of frailty: A Spanish multicenter prospective study	13
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	13
New targets for NAFLD	13
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study	13
Editorial Board page	13
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	13
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	13
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis	12
Contents	12
Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly	12
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regeneration	12
Editorial Board page	12
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)	12
Editorial Board page	12
Reply to: “Ductular reaction is a prognostic factor in primary biliary cholangitis”	12
Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia	11
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice	11
Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome	11
Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injury	11
Drug-induced liver injury in children: A nationwide cohort study from China	11
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	11
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis	11
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: Diagnostic value and link with histological lesions	11
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis	11
Contents	11
A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice	11
Defatting strategies in the current era of liver steatosis	11
Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	11
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts	11
Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)	11
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease	11
Copyright and information	10
Editorial Board page	10
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report	10
Contents	10
Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis	10
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation	10
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis	10
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	10
Copyright and information	10
Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans	10
Copyright and information	10
Contents	10
Implementing a new HCV model of care for people who use drugs	10
Daytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality	10
AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection	10
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	10
Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis	10
Contents	10
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study	10
Use of albumin infusion for cirrhosis-related complications: An international position statement	10
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	10
AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study	10
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases	9
C/EBPβ-VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD	9
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	9
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab	9
Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial	9
Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection	9
Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease	9
Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B	9
A transcriptomic intratumour heterogeneity-free signature overcomes sampling bias in prognostic risk classification for hepatocellular carcinoma	9
Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation	9
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis	9
24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ	9
Copyright and information	9
Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response	9
Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure	9
A comment on “Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes”	9
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis	9
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial	9
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care	8
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity	8
Interleukin-7-based identification of liver lymphatic endothelial cells reveals their unique structural features	8
Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis	8
Macrophage-derived IL-15 Imprints Peritoneal TRM-like CD8 T Cells in Cirrhosis and Spontaneous Bacterial Peritonitis	8
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	8
Contents	8
Duct-to-duct biliary reconstruction with or without an intraductal removable stent in liver transplantation: The BILIDRAIN-T multicentric randomised trial	8
Mechanisms and implications of recompensation in cirrhosis	8
Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses	8
Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis	8
A natural history study of paediatric non-alcoholic fatty liver disease over 10 years	8
Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data	8
An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma✰	8
Contents	8
Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis	8
Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma	8